Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2025Open Access

JAK2 46/1 (GGCC) Haplotype: A Biomarker for Oncogenesis, Risk Stratification, and Drug Resistance in Myeloproliferative Neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMaría Cecilia PerroneSSSara SergioBPBeatrice Pranzo

Discussion

Loading...

Member takes

Overview

Narrative review highlights JAK2 haplotype's role in oncogenesis and risk stratification for MPNs.

Key Points

  • The JAK2 46/1 haplotype increases susceptibility to hematological cancers, particularly MPNs, and is linked with drug resistance.
  • Key finding: the G allele of rs10974944 SNP in the haplotype correlates with MPNs progressing to myelofibrosis.
  • This narrative review covers landmark discoveries in hematological malignancies and how JAK2 influences cancer risk.
  • Understanding the JAK2 46/1 haplotype enhances risk stratification and aids in developing personalized treatments for patients.

Cite This Study

Perrone et al. (2025) studied this question.

synapsesocial.com/papers/68d41711713b0b5dfea629dchttps://doi.org/10.20944/preprints202509.0801.v1
View Full Paper
Ask AI
Bookmark
Share